Endocrine Abstracts

Introduction: Hyponatremia is the most common electrolyte disorder in hospitalized patients. SIADH is characterized by euvolemic hyponatremia with sodium and urine osmolality inappropriately high. The selective antagonist of the vasopressin V2 receptor (tolvaptan) helps to eliminate water free of solute (aquaresis), being effective in treating this condition.Objetive: Evaluate the efficacy and safety of tolvaptan in the treatment of SIADH.<p class="a...

Introduction: Cross-sex hormone treatment (CHT) in male-to-female (M2F) transsexuals affects the hemostatic balance, with the emergence of a prothrombotic state with the use of certain estrogen (oral ethinyl estradiol vs 17β estradiol). Testosterone administration to F2M transsexuals had an antithrombotic effect. In female-to-male in (F2M) transsexuals administration of testosterone seems to carry a mild antithrombotic effect.Objective: To quantify ...

Background: HNF1β mutations are one of the commonly identified genetic causes of renal malformations, but one of the less common forms of MODY. HNF1β is involved in the development of kidneys, liver, pancreas, intestine and urogenital tract. Patients can present with distinctive but highly variable clinical features. The aim of this study is to evaluate the clinical, biochemical and radiological variability of HNF1β variants and the challenge of management on th...

It is generally accepted that hepatic responses to α-adrenergic agonists are dependent on the redistribution of intracellular and also extracellular Ca2+. Besides, phenylephrine induces significant K+ flux changes and plasma membrane hyperpolarisation. Earlier it was shown that K+ channel blockers as well as chelating of extracellular Ca2+ with EGTA could inhibit phenylephrine-induced metabolic responses and activation of mitoch...

Objective: Objective to study the hypolipidemic efficacy, hepatoprotective activity, and tolerance of the fixed-dose combination of essential phospholipids with methionine (EPL+M) - Eslidine in the combination therapy with A in patients (pts) with cardiovascular diseases (CVD) and type 2 DM who suffer from hyperlipidemia (HL) in order to optimize their treatment in daily clinical practice.Subjects and methods: The trial enrolled 60 pts (mean age 58.1&#17...

Introduction: Therapeutic approach of patients (pts) with metastatic renal cell carcinoma (mRCC) may include the use of biological agents such as m-TOR inhibitors: temsirolimus (TM) and everolimus (EV). Its use is associated with metabolic dysfunction, especially with everolimus: hyperglycemia (37% TM treated pts vs 72% EV treated pts), hypercholesterolemia (25% TM treated pts vs 81% EV treated pts) and hypertriglyceridemia (30% TM treated pts vs 73% EV treated pts). Discontin...

Introduction: The thyroid is a multifunctional endocrine gland which, by its hormones, affects all the organs, metabolisms and nonspecific defence of the body. The aim of this study is to establish if endogenous thyroxin (FT4) is involved in the nonspecific defence of the organism.Material and methods: 94 patients were included in the study, 47 with hyperthyroidism and 47 with hypothyroidism, 81 women, 13 men aged 7–78. FT4 was...

Insulin resistance is a feature of polycystic ovary syndrome (PCOS) and is related to mitochondrial and endothelial function.We tested whether hyperandrogenic insulin-resistant women with PCOS, who have an increased risk of vascular disease, display impaired leukocyte-endothelium interactions, and mitochondrial dysfunction. This was a prospective controlled study conducted in an academic medical center.The study population consisted of 43 lean reproducti...

Type 1 diabetes is a chronic autoimmune disease with a subclinical prodromal period characterized by the presence of circulating antibodies to various islet cell proteins. Our main objective is to estimate the prevalence of diabetes-associated autoantibodies in a group of 1st degree relatives, compared to healthy control subjects. Also, we tried to assess the insulin secretory capacity in subjects having multiple antibodies using first phase insulin response (FPIR) to intraven...

M shows an antiproliferative effect. In vivo, M reduces TSH in type 2 diabetes mellitus (T2DM) and DTC aggressiveness in DTC with T2DM. The aim of the study was to evaluate in DTC diabetic (Gr1, n=30 under M 1500 mg/day) and non-diabetic without (Gr2, n=83) or under M (gr3, n=84; M 1000 mg/day) the adjuvant role of M. Clinical and laboratory examinations were performed up to 24 months. At baseline the DTC groups were similar for age, gender, tumor st...